Abstract:This study employs single‐cell transcriptomic analysis to identify subgroups of glioblastoma‐associated macrophages. Spatial transcriptomic analysis reveals the spatial distribution of macrophages within glioblastoma tissue. In vitro experiments demonstrate that inhibition of MS4A4A reduces the immunosuppressive function of M2‐type macrophages. In vivo experiments confirm that inhibition of MS4A4A enhances the response of glioblastoma to PD‐1 immunotherapy. This study provides new theoretical bases and molecular therapeutic targets for the diagnosis and treatment of glioblastoma. Introduction Glioblastoma (GBM) remains a challenging brain tumor to treat, with limited response to PD‐1 immunotherapy due to tumor‐associated macrophages (TAMs), specifically the M2 phenotype. This study explores the potential of MS4A4A (membrane spanning four domains, subfamily A, member 4A) inhibition in driving M2 macrophage polarization toward the M1 phenotype via the ferroptosis pathway to enhance the effectiveness of immunotherapy in GBM. Methods Single‐cell RNA sequencing and spatial transcriptomic analyses were employed to characterize M2 macrophages and MS4A4A expression in GBM. In vitro studies utilizing TAM cultures, flow cytometry, and western blot validations were conducted to assess the impact of MS4A4A on the tumor immune microenvironment and M2 macrophage polarization. In vivo models, including subcutaneous and orthotopic transplantation in mice, were utilized to evaluate the effects of MS4A4A knockout and combined immune checkpoint blockade (ICB) therapy on tumor growth and response to PD‐1 immunotherapy. Results Distinct subsets of GBM‐associated macrophages were identified, with spatial distribution in tumor tissue elucidated. In vivo experiments demonstrated that inhibiting MS4A4A and combining ICB therapy effectively inhibited tumor growth, reshaped the tumor immune microenvironment by reducing M2 TAM infiltration and enhancing CD8+ T‐cell infiltration, ultimately leading to complete tumor eradication. Conclusion MS4A4A inhibition shows promise in converting M2 macrophages to M1 phenotype via ferroptosis, decreasing M2‐TAM infiltration, and enhancing GBM response to PD‐1 immunotherapy. These findings offer a novel approach to developing more effective immunotherapeutic strategies for GBM.

The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets

The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities

Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities

Origin, activation, and targeted therapy of glioma-associated macrophages

Microglia and macrophages in glioblastoma: landscapes and treatment directions

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage

Tumor-associated macrophage-related strategies for glioma immunotherapy

Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma

The roles of glioma-associated macrophages/microglia and potential targets for anti-glioma therapy

TAMI-31. MACROPHAGE M1 INVASION PREDICTS POOR PROGNOSIS OF GLIOMA AND REVEALS A STRATEGY FOR GLIOBLASTOMA THERAPY

β2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages

An NFAT1-C3a-C3aR Positive Feedback Loop in Tumor-Associated Macrophages Promotes a Glioma Stem Cell Malignant Phenotype

Macrophages in Recurrent Glioblastoma as a Prognostic Factor in the Synergistic System of the Tumor Microenvironment

Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma

Macrophages/Microglia in the Glioblastoma Tumor Microenvironment

Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM

Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies

Microglia and Brain Macrophages as Drivers of Glioma Progression

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives